⏳ Fetching live dividend data...
Home › Calculator › AMGXF Dividend Calculator 2026
AnGes, Inc. · OTC
Price: $0.36 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in AMGXF → $291.16M in 10 years · $130,855.44/month
AnGes, Inc., a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characterized by impaired blood circulation in the legs. Beyond its lead therapy, AnGes is progressing a diverse portfolio of treatments. This includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine designed to mitigate inflammation, which is being investigated for ailments such as low back pain. The company is also working on therapies for atopic dermatitis and disc degeneration, alongside medical devices aimed at preventing vascular restenosis. Their efforts extend to the vaccine sector, encompassing therapeutic vaccines for cervical intraepithelial neoplasia (a precursor to cervical cancer), and DNA vaccines for high blood pressure, developed through a collaboration with Osaka University. Furthermore, AnGes is involved in multiple initiatives for coronavirus vaccines, including a partnership with Osaka University and an investigational plasmid DNA vaccine project with Brickell Biotech, Inc., targeting markets in the United States, South America, and elsewhere. To expand its commercial reach and development capabilities, AnGes has forged several strategic alliances. It collaborates with BioMarin Pharmaceutical Inc. for the Japanese marketing of Naglazyme, a drug for mucopolysaccharidosis VI. AnGes also partners with Mitsubishi Tanabe Pharma Corporation to market HGF Plasmid for peripheral arterial disease in the U.S. and Japan. Other key partnerships include SHIONOGI & CO., LTD. for the distribution of external-use drugs containing NF-kB decoy oligonucleotide for skin conditions, and Vical, Inc. for the development and commercialization of Allovectin, a cancer treatment. The company, originally known as AnGes MG, Inc., officially adopted the name AnGes, Inc. in July 2017, continuing its commitment to innovation in gene-based medicine.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AMGXF position with:
Real after-tax yield depends on where you live and how you hold AMGXF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 555.25% | 552.45% | $55,525 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 471.96% | 469.16% | $47,196 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 444.20% | 441.40% | $44,420 / yr |
| 🇬🇧 UK ISA | 0% | 555.25% | 552.45% | $55,525 / yr |
| 🇬🇧 UK Taxable | 8.75% | 506.67% | 503.87% | $50,667 / yr |
| 🇨🇦 TFSA | 0% | 555.25% | 552.45% | $55,525 / yr |
| 🇨🇦 CA Taxable | 25% | 416.44% | 413.64% | $41,644 / yr |
| 🇦🇺 Super (pension) | 15% | 471.96% | 469.16% | $47,196 / yr |
| 🇦🇺 AU Taxable | 30% | 388.67% | 385.87% | $38,868 / yr |
| 🇩🇪 DE Taxable | 26.375% | 408.80% | 406.00% | $40,880 / yr |
| 🇫🇷 FR Taxable | 30% | 388.67% | 385.87% | $38,868 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
AMGXF pays quarterly — 4 times per year. Next ex-div: TBD.
How AMGXF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AMGXF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AMGXF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
AnGes, Inc. (AMGXF) is currently trading at $0.36, 97% below its 52-week high. The current dividend yield is 555.25% based on an annual payout of $2.00 per share.
AnGes, Inc. (AMGXF) is a healthcare stock currently trading at $0.36 with a dividend yield of 555.25%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever